Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities
Plans to expand platform beyond hemophilia A
02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.
